不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel:ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:The relationship between clinical prognostic factors, microvascular density, and tumor-infiltrating lymphocytes with CD47 and SIRPα expression in diffuse large B cell lymphomas.
The relationship between clinical prognostic factors, microvascular density, and tumor-infiltrating lymphocytes with CD47 and SIRPα expression in diffuse large B cell lymphomas.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CD47与巨噬细胞上的信号调节蛋白α(SIRPα)相互作用,传递抗吞噬信号,使肿瘤细胞逃避免疫清除。本研究考察弥漫性大B细胞淋巴瘤(DLBCL)病例中CD47和SIRPα表达与关键临床预后因素、微血管密度(MVD)及TIL(肿瘤浸润淋巴细胞)的关系。研究使用122例DLBCL组织样本,通过组织芯片(TMA)及CD47、SIRPα、CD31和CD3免疫组化染色进行分析。CD47表达采用Allred评分系统评估;SIRPα表达则根据膜和胞质阳性表达比例进行定量。将临床资料(包括IPI评分、复发率和基因表达谱)与免疫组化结果进行关联分析。CD47表达评分为6与DLBCL-ABC亚型(p=0.029)、较高IPI评分(p=0.020)及较高复发率(p=0.021)显著相关。SIRPα高表达(染色≥25%)也与ABC亚型(p=0.022)和频繁复发(p=0.021)相关。
值得注意的是,微血管密度较高的病例SIRPα表达较低(p=0.013)。MVD与CD47或其他临床预后因素之间无显著关联。
此外,CD3阳性TIL比例较高与较低IPI评分呈负相关(p=0.005),但CD3与CD47-SIRPα之间未见显著关联。
本研究显示,DLBCL病例中CD47-SIRPα表达升高与不良预后指标及MVD降低存在部分关联。这些发现提示,靶向CD47-SIRPα轴可能为DLBCL提供新的治疗策略,尤其适用于预后不良患者。
CD47 interacts with signal regulatory protein alpha (SIRP ) on macrophages to deliver an anti-phagocytic signal, enabling tumor cells to evade immune destruction.
This study explores the relationship between CD47 and SIRP expression and key clinical prognostic factors, microvascular density (MVD), and tumor-infiltrating lymphocytes (TIL) in Diffuse Large B Cell Lymphoma (DLBCL) cases.
We analyzed tissue samples from 122 DLBCL cases using tissue microarray (TMA) blocks and immunohistochemical staining for CD47, SIRP , CD31, and CD3. CD47 expression was scored using the Allred scoring system, and SIRP expression was quantified based on the percentage of positive membranous and cytoplasmic expression.
Clinical data, including IPI scores, relapse rates, and gene expression profiles, were correlated with the immunohistochemical findings. CD47 expression score 6 was significantly associated with the DLBCL-ABC phenotype (p = 0. 029), higher IPI scores (p = 0. 020), and increased relapse rates (p = 0. 021). High SIRP expression ( 25 % staining) was also linked to the ABC phenotype (p = 0. 022) and frequent relapses (p = 0. 021).
Notably, cases with high microvascular density exhibited lower SIRP expression (p = 0. 013). There was no significant relationship between MVD and CD47 or other clinical prognostic factors.
Additionally, higher CD3-positive TIL percentages were inversely correlated with IPI scores (p = 0. 005), although no significant association was found between CD3 and CD47-SIRP . The study reveals that increased CD47-SIRP expression is partially linked to adverse prognostic indicators and reduced MVD in DLBCL cases.
These findings suggest that targeting the CD47-SIRP axis could offer a novel therapeutic approach in DLBCL, particularly for patients with poor prognostic features.
MEMBER ACCOUNT
登录成功会直接打开下一页。